(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
Two vials labeled GLOW from two different suppliers may contain the same three peptides in noticeably different proportions
doi: 10.1038/nature04290 72 FlorioM.HuttnerW
If plateaus extend beyond 4 to 6 weeks, evaluate diet and activity patterns before considering dose increases
Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fernndez Land L, Bray R, Linge J, Rodriguez A (2025) Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
This pregnancy issue is a real issue
